Atlas Trials

A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant

Clinical trial NCT07613359 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07613359
Sponsor
Takeda
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Antibody-Mediated Rejection (AMR)
Start date
2026-09-01
Primary completion
2029-01-15
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.